# Unravelling Sex Differences in the Genetic Architecture of Anxiety

Jihua Hu, MSc[1,2], Michelle K. Lupton, PhD[1,2,3], Enda M. Byrne, PhD[4], Nicholas G. Martin, PhD[1], David C. Whiteman, PhD[2,5], Catherine M. Olsen, PhD[2,5], Jodi T. Thomas, PhD[1,2], Sarah E. Medland, PhD[1,6,7], Katrina L. Grasby, PhD[1,2,3#], Brittany L. Mitchell, PhD[1,2,3#]

[1] Brain and Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
[2] School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
[3] School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia
[4] Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia
[5] Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
[6] School of Psychology, The University of Queensland, Brisbane, QLD, Australia
[7] School of Psychology and Counselling, Queensland University of Technology, Brisbane, QLD, Australia
# equally contributing

Corresponding author: Dr Brittany L. Mitchell; Email: brittany.mitchell@qimrb.edu.au
Jihua Hu; Email: Jihua.hu@qimrb.edu.au

Running title: Sex Differences in the Genetics of Anxiety

Keywords: Anxiety, Sex Differences, Genome-wide association study, Polygenic risk scores, Sex-linked, Genetics

Word count: 4008

**Abstract**

Anxiety disorders show striking sex differences in prevalence, symptoms, and clinical characteristics, shaping how they manifest and are experienced. Here, we report the first sex-specific meta-analysis of genome-wide association studies (GWAS) of anxiety, leveraging two of the largest biobank datasets, UK Biobank and All of Us, comprising 85,014 female cases with 130,817 controls and 36,724 male cases with 117,044 controls. Functional annotation, sex-specific polygenic scores (PGS), and genetic correlations were performed to assess genetic differences and functional implications. In females, 26 lead SNPs were significantly associated with anxiety, compared to six in males. Among these, seven lead SNPs in females and five in males demonstrated significantly different effect sizes across sexes. Although the genetic correlation between sexes was high, it was significantly different from one, indicating partially distinct genetic architectures. In addition, both the SNP-based observed and liability-scale heritabilities (assuming a 2:1 female-to-male prevalence ratio) were significantly higher in females. Gene-based tests and functional prioritization identified different genes associated with anxiety in females and males. Moreover, genetic correlation analyses revealed stronger associations of female anxiety with attention-deficit/hyperactivity disorder (ADHD) and body mass index (BMI), whereas male anxiety showed stronger correlations with waist-hip-ratio adjusted BMI. While the overall genetic architecture of anxiety is largely shared, our findings reveal distinct sex-specific genetic associations and correlations, highlighting the value of analysing the sexes separately to uncover genetic signals that may be masked in sex-combined samples.

**Introduction**

Anxiety disorders are the most common mental health disorders in the world, and a leading cause of disability-adjusted life years lost. Lifetime prevalence approaches one-third of the population, and demand for treatment is increasing, underscoring their substantial global public health burden (1).

Anxiety disorders are characterized by excessive and uncontrollable worry, persistent fear, and heightened perceptions of risk. Genetic factors have been estimated to contribute between 30% and 50% to anxiety disorders (2). Evidence from both twin studies (3) and genome-wide association studies (GWAS) indicates that much of this genetic liability is shared across anxiety disorders (4), including specific phobias, agoraphobia, social anxiety disorder, generalized anxiety disorder, and panic disorder (5). While the clinical diagnostic criteria vary for each disorder, the convergence of core symptoms and genetic liability supports examining anxiety disorders as a collective phenotype, referred to simply as "anxiety" in this study.

Striking sex differences have been observed in anxiety, particularly with regard to prevalence. Females are about twice as likely to be diagnosed as males (6). The prevalence difference between sexes has been consistently observed in specific anxiety disorders and across different cultures (7), and when all anxiety disorders are grouped together, the 2:1 prevalence ratio persists (8). Males and females also tend to manifest anxiety differently, with females commonly

reporting more internalizing symptoms and comorbid depression, while males are more likely to

exhibit externalizing symptoms and are more prone to substance use (7,9).

Previous studies have examined multiple underlying reasons for the observed differences in

anxiety prevalence between sexes, with many focusing on gender-related influences such as

masculinity norms that make men less likely to report anxiety (10), and more prone to using

substances as a coping strategy (11). Studies focusing on biological sex differences have

highlighted the potential roles of hormonal fluctuations (12), gut–brain axis interactions (13),

sex-dimorphic brain activation during emotion processing (14,15), as well as genetic components.

The contribution of genetic factors has primarily been examined through twin studies. Several

studies have reported higher heritability in girls, including general anxiety symptoms (16),

separation anxiety (17), and anxious and/or depressive symptoms (18). At the symptom level,

genetic factor loadings on insomnia within the anxiety symptoms were stronger and more

specific in females (19), and more recent work further demonstrated that anxiety itself was more

heritable in females (20). While a large twin study of multiple anxiety disorders found that

genetic contributions were highly similar in males and females (21). Overall, twin studies

showed mixed findings, with some evidence for stronger genetic influences in females and sex

differences in genetic effects.

To move beyond broad heritability estimates from twin studies, large-scale GWAS have begun

to elucidate the molecular basis of anxiety, identifying many independent significant SNPs

(ranging from 51 to 82 loci across studies) (4,22,23). However, none have focused on sex

heterogeneity. In this study, we conducted the first sex-specific GWAS meta-analysis for anxiety

to directly explore whether common genetic factors contribute to sex differences in anxiety. By

examining sex-specific genetic associations with anxiety, we aimed to comprehensively

characterize the genetic architecture of anxiety in females and males, and provide novel insights

into the molecular basis of observed sex differences in these disorders.

**Materials and methods**

**Study Population**

This study consists of participants from two of the largest available biobanks, the UK Biobank

(UKB) and All of Us (AoU) research program. UKB is a large nationwide cohort recruited

across 22 centers in the United Kingdom from 2006, consisting of 488,377 genotyped

individuals between the ages of 40 and 69 (24). AoU is an ongoing United States cohort

recruited from over 340 sites, currently comprising more than 414,000 genotyped participants

(25). Phenotypic information in UKB and AoU is derived from electronic health records (EHRs)

and self-reported survey data (24,25). In both cohorts, we excluded individuals without genotype

information, those with mismatched self-reported and genetic sex, and those who withdrew

consent. This study included participants who were classified as white British within the UKB

(26) and of European ancestry in AoU.

We identified participants who met DSM-5 criteria for the following anxiety disorders (5):

agoraphobia, social phobias, specific phobias, generalized anxiety disorders, panic disorders and

other phobic anxiety disorders as cases. In the UK Biobank, anxiety cases were defined by ICD-

10, self-reported professional diagnoses, CIDI short-form criteria, or a GAD-7 score $\geq$ 8.

Controls were participants without any self-reported or clinically recorded psychiatric diagnosis

of mental distress. In All of Us, cases were defined by EHR diagnoses of generalized anxiety,

panic, or phobic disorders, or by self-reported personal history of anxiety/panic disorder, while

controls were participants with EHR and genetic data but no documented diagnoses of major

psychiatric disorders. Case and control definitions in each cohort are detailed in the

**Supplementary Information** and **Supplementary Tables S1–S2**.

**Genome-wide association analyses**

Genome-wide association studies were performed using REGENIE (v 2.2.4) (27). Logistic

regressions were conducted on chromosomes 1 to 23 in a combined sample, as well as in females

and males separately. We assumed complete dosage compensation in females for testing

associations of anxiety and variants in the non-pseudoautosomal region of chromosome X

(genotypes in males were coded as 0/2). For UKB analyses, we adjusted for genotype array and

the first four genetic principal components (PCs); for AoU analyses, we adjusted for the first 10

PCs. In the sex-combined GWAS, we additionally adjusted for genetic sex. Genetic variants with

a minor allele frequency less than 1% or an imputation quality score less than 0.6 were excluded

from the association test results.

**Meta-analysis**

Meta-analysis of GWAS summary statistics from UKB and AoU was conducted using METAL

( v2020-05-05), using an inverse-variance weighted fixed-effects model. After meta-analysis,

ambiguous SNPs and indels with inconsistent allele frequencies were excluded. The final meta-

analysis comprised 369,599 participants, including 121,738 lifetime anxiety cases (85,014

females; 36,724 males) and 247,861 controls (130,817 females; 117,044 males) across both

cohorts. LD Score Regression (LDSC) (v1.0.1) (28) was used to estimate the intercept as a check

for inflation due to confounding from cryptic relatedness or population stratification.

**Characterisation of loci, functional annotation, and gene-based testing**

To identify trait-associated variants within linkage disequilibrium (LD) blocks, we defined lead

SNPs as those with $r^2 < 0.1$ and $P < 5\times10^{-8}$ using FUMA(v1.6.1) (29).

Lead SNPs and their proxies ($r^2 \geq 0.6$) were annotated in FUMA to prioritize genes, excluding

the major histocompatibility complex region:

1. Positional mapping that mapped SNPs to genes within 10 kb;

2. eQTL mapping used data from the Brain eQTL Almanac (Braineac), GTEx V8 brain and

adrenal gland datasets, focusing on significant eQTLs (FDR $\leq$ 0.05). The adrenal gland

was included due to its role in the fight-or-flight response (30);

3. Chromatin interactions were mapped using all available Hi-C data in FUMA (FDR <=

$1\times10^{-6}$).

MAGMA (Multi-marker Analysis of GenoMic Annotation) in FUMA was used for gene-based,

gene-set, and gene-expression association tests. Gene-based association, tested with the SNP-

wise mean model, included SNPs within 2 kb upstream and 1 kb downstream of genes, with

Bonferroni-corrected significance set at $P < 2.493\times10^{-6}$. Gene-set analysis explored shared

biological functions using curated gene sets and gene ontology (GO) terms from MSigDB

(v2023.1). Gene-expression analysis tested tissue-specific expression of associated genes using

GTEx V8 data across 54 and 30 tissue types.

**Heritability and genetic correlations**

SNP-based heritability was estimated using SBayesR (31), with a European-ancestry LD

reference panel derived from the UK Biobank. SNP-based heritability was converted to

heritability on liability (32) across a range of hypothesised population prevalences separately for

females and males.

We investigated the genetic correlation between sex-specific anxiety and anxiety associated traits

using LDSC, including mental health conditions, gastrointestinal symptoms, substance use,

metabolism, some social behaviors, and sex hormones. Where available, we used both combined

and sex-specific GWASs. All P-values were adjusted for FDR using the Benjamini-Hochberg

approach. To determine significant differences between female- and male-specific genetic

correlation with each trait, we calculated a Z-score as the difference between the sex-specific

genetic correlations divided by the sum of the squares of their respective standard errors, and a

two-tailed P-value from the Z-score (33); the corresponding adjusted P-value was computed

using the BH method (34).

**Polygenic scores**

To test whether our results were able to significantly predict anxiety in independent samples, we

calculated polygenic scores (PGS) using SBayesR (31). SBayesR is a Bayesian technique that

estimates the effect of SNPs from multi-normal distributions which may reflect the true

distribution of genetic variants. The estimated PGS were standardized using the *scale()* function

in R (v4.2.0).

We tested the association of PGS derived from our meta-analysis results with case-control

lifetime anxiety status and current anxiety symptoms (GAD-7) in two population cohorts (QSkin

(35) and PISA (36) respectively), as well as a large clinical, comorbid-depression cohort

(Australian Genetics of Depression Study; AGDS (37)) (**Supplementary Information, Table 1**).

While larger in size, it is important to note that in AGDS all the anxiety cases have comorbid

depression. Therefore, this sensitivity analysis may distinguish prediction between population-

based cohorts and clinical, comorbid-depression cohorts. To control for potential familial

relationships, we conducted a restricted maximum likelihood (REML) analysis using GCTA

(v1.91.7) (38), adjusting for the first 10 PCs and sex (combined analysis only).

To examine whether our PGS results were influenced by differences in sample sizes, and thus

statistical power, across our discovery GWASs, we downsampled the number of cases and

controls in the female-specific GWAS to match those in the male-specific GWAS for both UKB

and AoU, thereby maintaining the male case–control ratio. These downsampled female GWASs

were then meta-analyzed to obtain a downsampled meta-analysis result for females. In the

prediction cohorts, we also downsampled female cases and controls to the same numbers as

males. Downsampling was performed by random selection using the *sample()* function in R

(v4.2.0). We then repeated the above PGS regression analyses using these downsampled results.

**Results**

**GWAS of lifetime anxiety disorders in the total sample**

We conducted a meta-analysis of 369,599 European-ancestry individuals for lifetime anxiety,

including 121,738 cases. We identified 62 lead SNPs (**Table S3 and Figure 1A**) associated with

anxiety. Among these, 35 were not in LD with variants reported in recent large anxiety

GWASs (R2<0.8 or D'<0.9) (22,39). Using the same LD criteria and GWAS Catalog (40),

seven were not proxies of known mental health–related variants. Quality metrics of each cohort

GWAS are presented in Table S4, showing consistent SNP-based heritability with modest

genomic inflation, and corresponding Manhattan plots for UKB and AoU are shown in

**Supplementary Figures 1 and 2**. Cross-cohort LDSC analysis indicated high genetic correlation

between UKB and AoU GWAS (rg=0.81 in females and rg=0.93 in males), supporting their

combination in meta-analysis (**Table S4**). The sex-combined GWAS also showed strong genetic

correlation with the previously largest anxiety study (rg=0.92, P < $1\times10^{-300}$) (22). The observed

heritability of lifetime anxiety was estimated at 0.12 (SE=0.002) (**Table S5**).

**Sex-specific GWASs of anxiety disorders**

Sex-specific GWAS meta-analyses were performed using 215,831 (85,014 cases) females and

153,768 (36,724 cases) males. A total of 26 and six lead SNPs were identified in the female- and

male-specific GWAS, respectively (**Table S6, S7** and **Figure 1B**). The strongest association in

females was rs1000474011  (nearest gene: *CELF4*) on chromosome 18, and in males was

rs113613364 (nearest gene: *NEBL*) on chromosome 10. A single locus on chromosome 19

showed evidence of overlap between females and males ($R^2$=0.66), with no other shared lead

SNPs identified.

Of the 32 sex-specific lead SNPs, 12 exhibited statistically significant differences in effect size,

as determined by a Z-score test followed by FDR adjustment (**Figure 2**). Notably, one female

lead SNP, rs73460081 (nearest gene: *CCDC102B*), showed an opposite effect direction between

sexes, this SNP has also been prioritised to a redox-regulating gene *TMX3* based on chromatin

interactions.

**Sex-specific heritability and cross-sex genetic correlation**

SNP-based heritability of females was estimated as 0.14 (SD=0.003), and that of males was 0.12

(SD=0.004) on the observed scale. A Z-score test showed the SNP-based heritability was

significantly different between females and males (Z=5.42, P=$6.18\times10^{-8}$). Males exhibited

significantly higher genetic variance (Z=2.24, P=0.025), but also substantially greater residual

variance, resulting in higher heritability estimates in females **Figure 3A (Table S5)**.

To further evaluate sex-specific heritability in the context of varying population prevalences, we

converted observed-scale estimates to the liability scale across a range of assumed population

prevalences (0 to 0.6) (**Figure 3B**). When assuming the same population prevalence for both

sexes, males showed significantly higher liability-scale heritability (Z=2.09, P=0.037), consistent

with their greater estimated genetic variance (Figure 3A). In contrast, when assuming the

population prevalence of females was 0.30 and of males was 0.15 as reported in the U.S (41),

liability-scale heritability was higher in females (Z-test P=$8.9\times10^{-4}$).

The genetic correlation between females and males was 0.90 (SE=0.04), with the 95%

confidence interval of 0.82 to 0.97 (**Table S5**). A t-test indicated the genetic correlation

significantly differs from one (P=$8.8\times10^{-3}$), suggesting sex differences in the genetic architecture

of anxiety.

**Gene-level analysis**

To identify genes associated with lifetime anxiety, we used FUMA and prioritized 2,203 genes in

the combined GWAS, 413 in females, and 62 in males (**Tables S8–S10**). Of these, 25 were

shared between sexes (**Figure 3C**). Using MAGMA, 107, 29, and 4 significant genes were

identified in the combined, female-specific, and male-specific GWAS, respectively (**Tables**

**S11–S13**). Twenty-six female genes and three male genes overlapped with the combined results,

with only one gene shared between the sexes (**Figure 3D**).

The metabolism-related genes *B3GALTL* and *APOC1* were both prioritized by FUMA and

significant in MAGMA in males, and *B3GALTL* showed no association in females. A total of 24

genes were highlighted by both MAGMA and FUMA in the female-specific analyses. These

included genes involved in neuronal signaling and synaptic function, immune-related

butyrophilin family members, and several histone cluster genes. Gene-based scores from females

were associated with 13 gene ontology (GO) biological processes of chromatin regulation-related

gene sets, and olfactory transduction involved gene sets, while gene-based scores in males were

associated with four GO terms related to lipoprotein clearance and efflux (**Table S14**).

**Polygenic score associations**

Our combined anxiety disorder GWAS-derived $PGS_C$ showed a strong association with self-

reported lifetime anxiety in individuals in the QSkin population cohort (pseudo-$R^2$ =4.6% and  P

= $7.54 \times 10^{-51}$). When examining sex-specific PGS predictions, female-derived $PGS_F$ showed the

best prediction in both females and males (**Figure 4A, Table S15**). To exclude the potential

influence of PGS derived from GWAS with differing power on the predictive ability, we

downsized the GWAS for females and the combined sample to match that of males, and further

equalized the number of females and males in the prediction cohorts.

In the downsampled analyses of lifetime anxiety, the downsized $PGS_F$ (pseudo-$R^2$=1.6%)

predicted significantly more variance in females than $PGS_M$ (pseudo-$R^2$ = 0.69%), as the Z-test

comparing estimates yielded Z=2.19 (P=0.028). In males, the downsized $PGS_F$ (pseudo-$R^2$ =

1.7%) explained slightly more variance than $PGS_M$ ($R^2$ =1.4%), although this difference was not

statistically significant.

We also evaluated predictions of current levels of anxiety using the GAD-7 score in another

population cohort, PISA (**Figure 4B, Table S16**). Across both the original and downsized

analyses, polygenic scores explained a comparable proportion of variance in males and females.

In downsized females, $PGS_F$ explained slightly more variance ($R^2_F = 1.03\%$) than $PGS_M$ ($R^2_M =$

$0.89\%$). In males, $PGS_M$ predicted more variance ($R^2_M = 1.95\%$) compared to $PGS_F$ ($R^2_F$

$=1.70\%$). None of these differences in predictive value reached statistical significance.

Lastly, we tested the PGS associations in a clinical cohort where anxiety cases were comorbid

with depression (**Table S17, Figure S1A**). The trend of the predictive ability of the original PGS

was consistent with the QSkin and PISA cohorts. Once downsized, there was no difference in the

performance of the PGS derived from the female-specific, or the male-specific GWAS when

predicting into either sex (**Table S18, Figure S1B**).

**Sex-specific genetic correlations**

We tested genetic correlations between our sex-specific GWAS and sex-combined GWAS across

28 traits (**Figure 5, Table S19**). Seven traits showed significant sex differences (Z-test $P < 0.05$).

Females exhibited stronger correlations with attention deficit hyperactivity disorder (ADHD),

metabolic syndrome, body mass index (BMI), and lower educational attainment, while males

showed stronger correlations with bipolar disorder (all, type I, and type II). After FDR correction,

the sex difference in ADHD remained significant.

We further examined the genetic correlation of anxiety with available sex-specific GWAS of

BMI and waist-to-hip ratio adjusted for BMI (WHRadjBMI) (**Table S20**). The stronger genetic

correlation observed between females and BMI was maintained and remained significantly

greater than that in males (Z=2.42, P=0.015). For WHRadjBMI, which did not differ by sex

when using sex-combined GWAS, stratified analyses revealed a stronger correlation in males

(Z=3.05, P=0.002).

**Discussion**

Our study set out to investigate the genetic basis of sex differences in anxiety disorders by

leveraging sex-stratified GWAS and including the often-overlooked X chromosome. To our

knowledge, this is the first study to comprehensively examine potential sex-specific genetic

influences on anxiety disorders using this methodology.

Through sex-specific GWAS, we observed differences in significantly associated SNPs and

annotated genes between females and males. Seven female-specific and six male-specific lead

SNPs showed statistically significant differences in effect size between the sexes. In addition to

differences in specific SNPs, female- and male-stratified GWAS revealed very different

prioritized genes and corresponding biological processes. Genes prioritized in females were

enriched in chromatin regulation and olfactory transduction, while genes prioritized in males

were involved in the regulation of lipoprotein levels. Chromatin regulation, including

nucleosome remodeling, chromatin condensation, and histone methylation, influences gene

expression and epigenetics (42). Histone modifications have been linked to anxiety, stress

responses, and fear memory retrieval (42). The enrichment of chromatin interaction-related GO

processes in females, but not males, may suggest greater environmental sensitivity. Olfactory

function has been associated with anxiety, depression, and other psychiatric conditions (43), with

odor information primarily processed in the amygdala, a key stress-response region of the brain

(44). Evolutionarily, olfaction aids threat detection, social communication, and survival. Higher

anxiety levels have been linked to increased olfactory sensitivity (45), and women with anxiety

report greater odor awareness than men (46), consistent with our findings that olfactory transduction-related genes are enriched only in females.

As for the male-specific enrichment in lipoprotein metabolism, both acute and chronic stress lead to elevated levels of lipoprotein in humans. This increase has been explained as a part of the body's response to provide energy for the fight-or-flight stress-coping mechanism (47). Higher lipoprotein levels have been found to be associated with depression in males (48), while females with higher lipoprotein levels were more likely to have lower scores on depression and anxiety tests (49). These differences may be due to the different lipoprotein metabolism in females and males, which is influenced by estrogen and testosterone-specific signaling pathways (50). The gene enrichment results suggest that genetic factors may contribute to these previously observed sex differences.

Moreover, the male-specific enrichment of the lipoprotein metabolism pathway aligns with our genetic correlation results, which showed a stronger association between waits-hip-ratio adjusted BMI (WHRadjBMI) and anxiety in males. WHRadjBMI reflects central fat distribution and is more closely linked to insulin-related dysregulation and lipoprotein metabolism than BMI (51), thereby providing a plausible mechanism for male-specific anxiety risk. This interpretation is consistent with findings from a large Norwegian population-based cohort, which reported that WHR was associated with anxiety in men but not women (52). Interestingly, BMI showed a stronger genetic correlation with anxiety in females, consistent with epidemiological studies reporting that obesity and anxiety are more strongly linked in women (53,54). A neuroimaging study further showed that higher BMI was associated with significantly stronger stress-related brain responses in females (55), whereas an epidemiological study of young adults found that higher perceived stress was linked to lower BMI in men (56). Overall, these findings suggest that

different adiposity pathways underlie sex-specific genetic overlaps between anxiety and body

weight, with overall adiposity being more relevant in females and central fat distribution in

males.

The genetic correlation between females and males was high but significantly different from one,

indicating that the genetic architecture of anxiety is largely shared but not completely identical

across sexes. In sex-specific PGS analyses with matched sample size, the only significant

difference was that female-derived PGS predicted female anxiety more strongly than male-

derived PGS in the population cohort. This finding is consistent with higher SNP heritability

observed in females and the expectation that same-sex PGS should align more closely with the

target phenotype. In males, female- and male-derived PGS performed similarly, with female-

PGS performing slightly better. This may reflect the considerable similarity in genetic effects

between sexes and lower SNP-based heritability observed in males. In the QSkin population

cohort specifically, anxiety was assessed with a single broad self-report question ('have you

been diagnosed, experienced, or treated for anxiety?') (35). Such single-item measures have only

moderate sensitivity and specificity compared with multi-item scales (57). Underreporting

among men (10) may have further contributed to weaker prediction in males relative to other

cohorts. In the clinical depression cohort, where anxiety was assessed using DSM-5 criteria (37),

and in the GAD-7 symptom-based analyses, PGS showed the expected pattern of stronger same-

sex prediction. Although none of these differences reached statistical significance, this aligns

with previous studies of sex-specific PGS in depression, which similarly reported no significant

differences despite observing the same pattern (58). Taken together, these findings suggest that

while subtle sex-specific patterns can be observed, the sex-specific PGS are comparable in

predictive ability.

We explored genetic correlations of our sex-specific anxiety GWASs with sex-combined GWAS

of other traits, finding that some traits were more strongly correlated in one sex. Bipolar

disorders, characterized by alternating manic and depressive episodes, showed a higher genetic

correlation with anxiety in type II (depressive episodes are predominant) than type I bipolar

disorder (distinguished by manic episodes). While the sex difference in genetic correlation with

bipolar disorder did not survive FDR correction (FDR-adjusted P=0.064), it was nominally

significant, with males showing stronger correlations across both subtypes. These findings

suggest a potential sex-specific genetic relationship between anxiety and bipolar disorder. Given

that no consistent sex differences have been observed in bipolar disorder (59), our findings may

offer a new perspective on the relationship between anxiety and bipolar disorder through a sex-

specific approach. ADHD, despite being more prevalent in males and showing a similar genetic

architecture across sexes (60,61), displayed a significantly stronger genetic correlation with

female anxiety. This finding is consistent with ADHD and anxiety being more frequently

comorbid in females (62). It further implies that in females, ADHD risk may be more likely to

manifest through anxiety symptoms, which can result in anxiety diagnoses overshadowing

ADHD and lead to under-recognition of ADHD in females (63).

Overall, this study provides evidence of genetic sex differences in anxiety at many aspects,

including sex specific variants, prioritized genes, enriched biological processes, genetic

architecture, and genetic correlation with other traits. Our findings indicate that sex not only

shapes the genetic architecture of anxiety itself but also influences its genetic overlap with

comorbid psychiatric conditions. Standard GWAS often assume a shared genetic architecture

across sexes, potentially masking sex-specific effects. This was illustrated in the WHRadjBMI

analyses, where sex-specific genetic correlations with anxiety were not detectable in the

combined GWAS. Given that sex heterogeneity is common in complex traits, ignoring these

differences may oversimplify the underlying biology. Future studies conducting sex-specific

GWAS on a larger scale are essential for fully capturing the distinct genetic contributions to

anxiety in males and females.

Our study is the first to conduct a large-scale sex-stratified GWAS of anxiety, demonstrating

significant sex differences in heritability and genetic correlations with other traits. These findings

highlight the value of a sex-specific approach for uncovering genetic architecture that may be

obscured in combined analyses. However, our results should be considered in light of some

limitations. The smaller male sample size reduces statistical power compared to females, and

larger samples will be needed to clarify sex differences or commonalities. Additionally, the UK

Biobank and All of Us cohorts are not fully representative of the general population, which may

limit generalizability. Future sex-specific GWAS in other traits with known heterogeneity could

enhance understanding of sex-specific genetic factors and shared genetic architecture across

traits.

**Acknowledgements**

J.H was funded by a QIMR PhD scholarship. B.L.M (APP2017176), K.L.G (APP1173025),

S.E.M (APP1172917 and APP2025674), and D.C.W (APP2026567) are supported by

Investigator Grants from the National Health and Medical Research Council of Australia

(NHMRC). E.M.B are supported by Research Excellence grant (1198304) from NHMRC Centre,

and the University of Queensland Health Research Accelerator Program. The QSkin Study is

supported by a Clinical Trials and Cohort Grant [APP1185416] from NHMRC. PISA was funded

by an NHMRC Dementia Research Team Grant [APP1095227]. This study makes use of data

from UK Biobank (Project ID: 25331).

We sincerely thank all UKB, All of Us, AGDS, PISA and QSkin participants for their time and

contributions to this study. We also appreciate everyone involved in the study's conception,

implementation, media campaign, and data cleaning.

**Disclosures**

The authors declare no conflicts of interest.

**Author contributions**

J.H performed the analyses, wrote the manuscript and integrated input and feedback from all co-

authors. B.L.M and K.L.G designed and supervised the study. Support and input was provided

by S.E.M, who along with M.K.L, E.M.B, N.G.M, D.C.W, C.M.O were responsible for the

cohort design, genotyping, and data acquisition, processing and quality control. J.T.T provided

support with analyses. All authors read and approved the final manuscript.

**References**

1.  Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec
27;328(24):2431–45.

2.  Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM, et al. Anxiety disorders.
Nat Rev Dis Primer. 2017 May 4;3(1):1–19.

3.  Tambs K, Czajkowsky N, Røysamb E, Neale MC, Reichborn-Kjennerud T, Aggen SH, et al.
Structure of genetic and environmental risk factors for dimensional representations of DSM-
IV anxiety disorders. Br J Psychiatry J Ment Sci. 2009 Oct;195(4):301–7.

4.  Mitchell BL, Skelton M, Wang R, Kuile AR ter, Murphy AE, Morneau-Vaillancourt G, et al.
Genome-wide meta-analysis identifies genetic risk factors and implicates multiple body
systems in panic attacks and disorder [Internet]. medRxiv; 2025 [cited 2025 Sept 9]. p.

2025.06.15.25329656. Available from:
https://www.medrxiv.org/content/10.1101/2025.06.15.25329656v1

5. Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed. Arlington, VA, US:
American Psychiatric Publishing, Inc.; 2013. xliv, 947 p. (Diagnostic and statistical manual
of mental disorders: DSM-5™, 5th ed).

6. Fisher K, Seidler ZE, King K, Oliffe JL, Robertson S, Rice SM. Men's anxiety, why it
matters, and what is needed to limit its risk for male suicide. Discov Psychol. 2022;2(1):18.

7. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders:
Prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011 Aug
1;45(8):1027–35.

8. Yeretzian ST, Sahakyan Y, Kozloff N, Abrahamyan L. Sex differences in the prevalence and
factors associated with anxiety disorders in Canada: A population-based study. J Psychiatr
Res. 2023 Aug 1;164:125–32.

9. Farhane-Medina NZ, Luque B, Tabernero C, Castillo-Mayén R. Factors associated with
gender and sex differences in anxiety prevalence and comorbidity: A systematic review. Sci
Prog. 2022;105(4):368504221135469.

10. Clark LauraH, Hudson JenniferL, Haider T. Anxiety Specific Mental Health Stigma and
Help-Seeking in Adolescent Males. J Child Fam Stud. 2020 July 1;29(7):1970–81.

11. Harris MG, Baxter AJ, Reavley N, Diminic S, Pirkis J, Whiteford HA. Gender-related
patterns and determinants of recent help-seeking for past-year affective, anxiety and
substance use disorders: findings from a national epidemiological survey. Epidemiol
Psychiatr Sci. 2016 Dec;25(6):548–61.

12. Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-
related disorders? The potential role of sex hormones. Lancet Psychiatry. 2017 Jan
1;4(1):73–82.

13. Holingue C, Budavari AC, Rodriguez KM, Zisman CR, Windheim G, Fallin MD. Sex
Differences in the Gut-Brain Axis: Implications for Mental Health. Curr Psychiatry Rep.
2020 Nov 20;22(12):83.

14. Gardener EKT, Carr AR, Macgregor A, Felmingham KL. Sex differences and emotion
regulation: an event-related potential study. PloS One. 2013;8(10):e73475.

15. Donner NC, Lowry CA. Sex differences in anxiety and emotional behavior. Pflugers Arch.
2013 May;465(5):601–26.

16. Ask H, Torgersen S, Seglem KB, Waaktaar T. Genetic and environmental causes of variation
in adolescent anxiety symptoms: a multiple-rater twin study. J Anxiety Disord. 2014
May;28(4):363–71.

17. Eaves LJ, Silberg JL, Meyer JM, Maes HH, Simonoff E, Pickles A, et al. Genetics and
Developmental Psychopathology: 2. The Main Effects of Genes and Environment on
Behavioral Problems in the Virginia Twin Study of Adolescent Behavioral Development. J
Child Psychol Psychiatry. 1997;38(8):965–80.

18. Boomsma DI, Van Beijsterveldt CEM, Hudziak JJ. Genetic and environmental influences on
Anxious/Depression during childhood: a study from the Netherlands Twin Register. Genes
Brain Behav. 2005;4(8):466–81.

19. Kendler KS, Heath AC, Martin NG, Eaves LJ. Symptoms of anxiety and symptoms of
depression. Same genes, different environments? Arch Gen Psychiatry. 1987
May;44(5):451–7.

20. Burton KLO, Williams LM, Richard Clark C, Harris A, Schofield PR, Gatt JM. Sex
differences in the shared genetics of dimensions of self-reported depression and anxiety. J
Affect Disord. 2015 Dec 1;188:35–42.

21. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. The Structure of Genetic and
Environmental Risk Factors for Anxiety Disorders in Men and Women. ARCH GEN
PSYCHIATRY. 2005;62.

22. Friligkou E, Løkhammer S, Cabrera-Mendoza B, Shen J, He J, Deiana G, et al. Gene
discovery and biological insights into anxiety disorders from a large-scale multi-ancestry
genome-wide association study. Nat Genet. 2024 Oct;56(10):2036–45.

23. Strom NI, Verhulst B, Bacanu SA, Cheesman R, Purves KL, Gedik H, et al. Genome-wide
association study of major anxiety disorders in 122,341 European-ancestry cases identifies
58 loci and highlights GABAergic signaling [Internet]. medRxiv; 2024 [cited 2025 Sept 10].
p. 2024.07.03.24309466. Available from:
https://www.medrxiv.org/content/10.1101/2024.07.03.24309466v1

24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.

25. Bick AG, Metcalf GA, Mayo KR, Lichtenstein L, Rura S, Carroll RJ, et al. Genomic data in
the All of Us Research Program. Nature. 2024 Mar;627(8003):340–6.

26. MacGregor S, Ong JS, An J, Han X, Zhou T, Siggs OM, et al. Genome-wide association
study of intraocular pressure uncovers new pathways to glaucoma. Nat Genet. 2018
Aug;50(8):1067–71.

27. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al.
Computationally efficient whole-genome regression for quantitative and binary traits. Nat
Genet. 2021 July;53(7):1097–103.

28. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score
regression distinguishes confounding from polygenicity in genome-wide association studies.
Nat Genet. 2015 Mar;47(3):291–5.

29. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation
of genetic associations with FUMA. Nat Commun. 2017 Nov 28;8(1):1826.

30. Hinds JA, Sanchez ER. The Role of the Hypothalamus–Pituitary–Adrenal (HPA) Axis in
Test-Induced Anxiety: Assessments, Physiological Responses, and Molecular Details.
Stresses. 2022 Mar;2(1):146–55.

31. Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, et al. Improved
polygenic prediction by Bayesian multiple regression on summary statistics. Nat Commun.
2019 Nov 8;10(1):5086.

32. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating Missing Heritability for Disease
from Genome-wide Association Studies. Am J Hum Genet. 2011 Mar 11;88(3):294–305.

33. Blokland GAM, Grove J, Chen CY, Cotsapas C, Tobet S, Handa R, et al. Sex-Dependent
Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biol
Psychiatry. 2022 Jan 1;91(1):102–17.

34. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.

35. Olsen CM, Green AC, Neale RE, Webb PM, Cicero RA, Jackman LM, et al. Cohort profile:
the QSkin Sun and Health Study. Int J Epidemiol. 2012 Aug;41(4):929–929i.

36. Lupton MK, Robinson GA, Adam RJ, Rose S, Byrne GJ, Salvado O, et al. A prospective
cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing:
Genes, Brain and Behaviour (PISA). NeuroImage Clin. 2021 Jan 1;29:102527.

37. Byrne EM, Kirk KM, Medland SE, McGrath JJ, Colodro-Conde L, Parker R, et al. Cohort
profile: the Australian genetics of depression study. BMJ Open. 2020 May 1;10(5):e032580.

38. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex
Trait Analysis. Am J Hum Genet. 2011 Jan 7;88(1):76.

39. Purves KL, Coleman JRI, Meier SM, Rayner C, Davis KAS, Cheesman R, et al. A major
role for common genetic variation in anxiety disorders. Mol Psychiatry. 2020
Dec;25(12):3292–303.

40. Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, et al. The NHGRI-EBI GWAS
Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 2023 Jan
6;51(D1):D977–85.

41. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender Differences in Anxiety Disorders:
Prevalence, Course of Illness, Comorbidity and Burden of Illness. J Psychiatr Res. 2011
Aug;45(8):1027–35.

42. Ell MA, Schiele MA, Iovino N, Domschke K. Epigenetics of Fear, Anxiety and Stress –
Focus on Histone Modifications. Curr Neuropharmacol. 2023 Sept 1;22(5):843.

43. Marin C, Alobid I, Fuentes M, López-Chacón M, Mullol J. Olfactory Dysfunction in Mental
Illness. Curr Allergy Asthma Rep. 2023 Mar 1;23(3):153–64.

44. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses.
Nat Rev Neurosci. 2009 June;10(6):397–409.

45. Galliot E, Laurent L, Hacquemand R, Pourié G, Millot JL. Fear-like behavioral responses in
mice in different odorant environments: Trigeminal versus olfactory mediation under low
doses. Behav Processes. 2012 June 1;90(2):161–6.

46. Dal Bò E, Gentili C, Castellani A, Tripodi C, Fischmeister FPS, Cecchetto C. Olfactory
meta-cognition in individuals with depressive and anxiety symptoms: The differential role of
common and social odors. J Affect Disord. 2022 July 1;308:259–67.

47. Brindley DN, McCann BS, Niaura R, Stoney CM, Suarez EC. Stress and lipoprotein
metabolism: Modulators and mechanisms. Metabolism. 1993 Sept 1;42(9, Supplement 1):3–
15.

48. Bao J, Zheng S, Huang J, Xie X, Zhang J, Yang S, et al. Mental health is correlated with
lipoprotein(a) levels in male patients with premature coronary heart disease. Ann Palliat Med.
2021 June;10(6):6482–92.

49. Suarez EC. Relations of trait depression and anxiety to low lipid and lipoprotein
concentrations in healthy young adult women. Psychosom Med. 1999;61(3):273–9.

50. Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein
metabolism. Mol Metab. 2018 May 16;15:45.

51. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New
genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015
Feb;518(7538):187–96.

52. Rivenes AC, Harvey SB, Mykletun A. The relationship between abdominal fat, obesity, and
common mental disorders: Results from the HUNT Study. J Psychosom Res. 2009 Apr
1;66(4):269–75.

53. Jorm AF, Korten AE, Christensen H, Jacomb PA, Rodgers B, Parslow RA. Association of
obesity with anxiety, depression and emotional well□being: a community survey. Aust N Z J
Public Health. 2003 Aug 1;27(4):434–40.

54. Barry D, Pietrzak RH, Petry NM. Gender Differences in Associations Between Body Mass
Index and DSM-IV Mood and Anxiety Disorders: Results from the National Epidemiologic
Survey on Alcohol and Related Conditions. Ann Epidemiol. 2008 June;18(6):458–66.

55. Kühnel A, Hagenberg J, Knauer-Arloth J, Ködel M, Czisch M, Sämann PG, et al. Stress-
induced brain responses are associated with BMI in women. Commun Biol. 2023 Oct
11;6(1):1031.

56. Suglia SF, Pamplin JR, Forde AT, Shelton RC. Sex differences in the association between
perceived stress and adiposity in a nationally representative sample. Ann Epidemiol. 2017
Oct 1;27(10):626–31.

57. Turon H, Carey M, Boyes A, Hobden B, Dilworth S, Sanson-Fisher R. Agreement between a
single-item measure of anxiety and depression and the Hospital Anxiety and Depression
Scale: A cross-sectional study. PLOS ONE. 2019 Jan 4;14(1):e0210111.

58. Silveira PP, Pokhvisneva I, Howard DM, Meaney MJ. A sex-specific genome-wide
association study of depression phenotypes in UK Biobank. Mol Psychiatry. 2023
June;28(6):2469–79.

59. Diflorio A, Jones I. Is sex important? Gender differences in bipolar disorder. Int Rev
Psychiatry. 2010 Oct;22(5):437–52.

60. Martin J, Taylor MJ, Rydell M, Riglin L, Eyre O, Lu Y, et al. Sex-specific manifestation of
genetic risk for attention deficit hyperactivity disorder in the general population. J Child
Psychol Psychiatry. 2018;59(8):908–16.

61. Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al.
Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and
implicate several cognitive domains. Nat Genet. 2023 Feb;55(2):198–208.

62. Young S, Adamo N, Ásgeirsdóttir BB, Branney P, Beckett M, Colley W, et al. Females with
ADHD: An expert consensus statement taking a lifespan approach providing guidance for
the identification and treatment of attention-deficit/ hyperactivity disorder in girls and
women. BMC Psychiatry. 2020 Aug 12;20(1):404.

63. Martin J. Why are females less likely to be diagnosed with ADHD in childhood than males?
Lancet Psychiatry. 2024 Apr 1;11(4):303–10.

**Legends for Tables and Figures**

**Fig. 1: Manhattan plots of analyzed genetic variants for lifetime anxiety.** A: Manhattan plot

of anxiety disorders in the total sample (cases=121,738; controls=247,861); B: Miami plot of

GWAS for females (cases=85,014; controls=130,817) are plotted above the X-axis, for males

(cases=36,724; controls=117,044) are shown below the X-axis.

**Fig. 2: Forest plot of effect sizes and 95% confidence intervals of lead SNPs from the sex-**

**specific GWAS.** Effect size estimates (β) and 95% confidence intervals are shown for lead SNPs

identified in sex-stratified GWAS. The top panel presents lead SNPs from the female GWAS

with corresponding estimates in two sexes; the bottom panel presents lead SNPs from the male

GWAS with corresponding estimates. SNP labels in bold indicate significant differences

between female and male effect estimates, based on a Z-test for effect size differences with FDR-

adjusted $P < 0.05$.

**Figure 3. Sex-specific genetic architecture and gene overlap in anxiety.** A: Observed SNP-

based heritability and variance components (genetic and residual) estimated separately for

females and males using SBayesR. B: Liability-scale heritability estimates across a range of

assumed population prevalences (0–0.6) for each sex, based on observed-scale heritability and

case proportions in each sex. C: Overlap of significant genes identified by MAGMA in females

and males. D: Overlap of FUMA-prioritized genes across sexes.

**Figure 4: Sex-Specific Polygenic Scores (PGS) in Lifetime Anxiety and GAD-7** A: PGS

prediction for lifetime anxiety in females and males in the population cohort (QSkin). B: PGS

prediction for GAD-7 in the population cohort (PISA).

Bars in different colors represent PGS derived from different GWAS. The X-axis indicates the

sex of the target sample. P-values for the beta coefficient are shown at the top of the 95%

confidence interval bar. To ensure comparability, an additional downsampled prediction was

performed in which female-specific GWAS were downsized to match the male-specific GWAS,

and the number of females in the target cohorts was also downsampled to equal that of males.

**Fig. 5: Forest plot of sex dependent genetic correlation.** Genetic correlation (rg) estimates are

represented by triangles (females) and squares (males). Horizontal bars indicate the 95%

confidence intervals. P-values from the Z-tests comparing sex-specific rg estimates for each trait

are shown on the right; significant values (P < 0.05) are shown in bold, and those passing the

FDR threshold are additionally marked with an asterisk (*).

**Table 1: Sex Distribution in Cohorts Used for Polygenic Score (PGS) Predictions**

**Tables**

**Table 1: Sex Distribution in Cohorts Used for Polygenic Score (PGS) Predictions**

| Cohort | Measurement | Nfemales (cases/controls) | Nmales (cases/controls) | Ncombined (cases/controls) |
|--------|-------------|---------------------------|-------------------------|----------------------------|
| Qskin  | Self-report | 1,528/6,481               | 819/6,238               | 2,347/12,719               |
| PISA   | GAD-7       | 3,263                     | 1,605                   | 4,868                      |
| AGDS   | Self-report | 8,278/6,481               | 2,902/6,238             | 11,180/12,719              |
| AGDS   | GAD-7       | 5,556                     | 1,681                   | 7,282                      |

A

B

females

males

| Phenotype | | P of Z score |
|---|---|---|
| Anxiety | | P = 0.635 |
| Depression | | P = 0.070 |
| Bipolar All | | **P = 0.009** |
| Bipolar I | | **P = 0.006** |
| Bipolar II | | **P = 0.014** |
| Schizophrenia | | P = 0.093 |
| ADHD | | **P < 0.001*** |
| Autism | | P = 0.058 |
| Anorexia nervosa | | P = 0.611 |
| OCD | | P = 0.381 |
| PTSD | | P = 0.677 |
| Peptic ulcer disease (PUD) | | P = 0.996 |
| Gastro-oesophageal reflux disease (GORD) | | P = 0.851 |
| Irritable bowel syndrome (IBS) | | P = 0.958 |
| Inflammatory bowel disease (IBD) | | P = 0.081 |
| Cigrarettes per day | | P = 0.527 |
| Smoking initiation | | P = 0.181 |
| Drinks per week | | P = 0.731 |
| Substance use (combination) | | P = 0.605 |
| Cannabis additiction | | P = 0.963 |
| Metabolic syndrome | | **P = 0.039** |
| Wasit-hip-ratio (WHR) | | P = 0.361 |
| Body mass index (BMI) | | **P = 0.009** |
| WHR adjusted BMI | | P = 0.390 |
| Education attainment | | **P = 0.044** |
| Speeding | | P = 0.187 |
| Sex hormone binding globulin (SHBG) | | P = 0.105 |
| Testosterone | | P = 0.508 |

Genetic correlation with 95% CI

Group ■ Male ▲ Female